title: Graft versus leukemia effect after transplantation with interleukin-2-activated bone marrow. Correlation with eradication of residual disease.
abstract: IL-2 has been used after autologous BMT (ABMT) with the aim of inducing graft versus leukemia (GVL) effect. Our studies in mice have shown that IL-2 therapy induces GVL effect when employed after BMT with bone marrow (BM) that has been activated with IL-2 in vitro (ABM). The present study was carried out to define the time of optimal GVL effect after BMT so that the immunomodulatory approaches could be concentrated at the time of maximum GVL effect. Our data show that GVL effect was induced if IL-2 was instituted immediately after BMT with ABM in mice with acute myeloid leukemia; institution of IL-2 1 week after BMT with ABM did not induce GVL effect. IL-2 therapy instituted immediately or 1 week after BMT with fresh bone marrow (FBM) did not induce any GVL effect. A significant increase in the NK activity was noticed whether IL-2 was instituted immediately or 1 week after BMT, either with FBM or with ABM. To evaluate the ability of IL-2 in the eradication of residual disease from the autograft and the host, BM with variable infiltration with leukemia was activated with IL-2 and used for BMT in leukemic mice. The GVL effect of BM with minimal leukemic infiltration (absence of morphologically demonstrable disease) was comparable to the GVL effect of normal BM. These findings suggest that: (a) maximum GVL effect after BMT with ABM is concentrated in the early post-transplant period possibly because of minimal residual disease during this time; (b) an increase in the NK activity induced by IL-2 therapy may not predict for an improved GVL effect; and (c) for optimum GVL effect, BM with minimal leukemic infiltration should be activated with IL-2 before BMT.
authors.affiliation: Bone Marrow Transplantation Program, Georgetown University, Washington, D.C. 20007.
authors.forename: B S
authors.initials: BS
authors.lastname: Charak
authors.forename: R K
authors.initials: RK
authors.lastname: Brynes
authors.forename: M
authors.initials: M
authors.lastname: Chogyoji
authors.forename: V
authors.initials: V
authors.lastname: Kortes
authors.forename: M
authors.initials: M
authors.lastname: Tefft
authors.forename: A
authors.initials: A
authors.lastname: Mazumder
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000473:pathology; D016465:Bone Marrow Purging / Q000379:methods; D016026:Bone Marrow Transplantation / Q000379:methods; D005260:Female; D006085:Graft Survival; D007376:Interleukin-2 / Q000627:therapeutic use*; D007942:Leukemia, Experimental / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D014182:Transplantation, Autologous; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins